Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
D
Dacrema, Valerio
Pharmacology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(
P 117
)
SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Valerio Dacrema
Favorite
Dagrada, Gianpaolo
Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(
P 01
)
ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Gianpaolo Dagrada
Favorite
(
P 016
)
ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Gianpaolo Dagrada
Favorite
(
P 170
)
ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Gianpaolo Dagrada
Favorite
(
P 188
)
PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Gianpaolo Dagrada
Favorite
Dahi, Anthony
Sarcoma Oncology Center
(
P 122
)
AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Anthony Dahi
Favorite
(
P 126
)
GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Anthony Dahi
Favorite
(
P 132
)
PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Anthony Dahi
Favorite
(
P 137
)
SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Anthony Dahi
Favorite
Dai, Dong
Daiichi Sankyo, Inc.
(
P 066
)
CHARACTERISTICS OF PATIENTS RECEIVING PEXIDARTINIB IN THE REAL-WORLD SETTING: A CROSS-SECTIONAL SURVEY
Dong Dai
Favorite
Daley, Jessica
University of Pittsburgh, UPMC Children's Hospital of Pittsburgh
(
P 036
)
STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Jessica Daley
Favorite
D'Amato, Gina
University of Miami/Sylvester Comprehensive Cancer Center
(
P 07
)
HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Gina D'Amato
Favorite
D'Amato, Gina
Sylvester Comprehensive Cancer Center
(
P 070
)
COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Gina D'Amato
Favorite
(
P 234
)
DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Gina D'Amato
Favorite
D'Amato, Gina
University of Miami/Sylvester Comprehensive Cancer Center
(
P 263
)
COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Gina D'Amato
Favorite
Damayanti, Nuri
Indiana University
(
P 192
)
TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Nuri Damayanti
Favorite
D'Ambrosio, Lorenzo
University of Torino
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Lorenzo D'Ambrosio
Favorite
Dandu, Navya
University of Illinois Chicago
(
P 277
)
BEARING SELECTION IN PROXIMAL FEMORAL REPLACEMENT: A COMPARISON OF CLINICAL OUTCOMES
Navya Dandu
Favorite
(
P 300
)
RECONSTRUCTION FOLLOWING SACROILIAC TUMOR RESECTION: A SYSTEMATIC REVIEW
Navya Dandu
Favorite
D'Angelo, Sandra
Memorial Sloan Kettering Cancer Center
(
P 134
)
PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Sandra D'Angelo
Favorite
Danieau, Geoffroy
Research Institute of the McGill University Health Center
(
P 022
)
EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS
Geoffroy Danieau
Favorite
(
P 030
)
OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Geoffroy Danieau
Favorite
(
P 232
)
DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA
Geoffroy Danieau
Favorite
Danieli, Maria
Fondazione Irccs Istituto Nazionale Dei Tumori
(
P 052
)
PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Maria Danieli
Favorite
DANOUSSOU-LAMBOURSIN, Divya
Institut Gustave roussy
(
P 217
)
PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Divya DANOUSSOU-LAMBOURSIN
Favorite
Dare, Anna
University of Toronto
(
P 088
)
RETHINKING THE MANAGEMENT OF AGGRESSIVE ANGIOMYXOMA: A REPORT FROM FOUR CANADIAN SARCOMA CENTRES.
Anna Dare
Favorite
Darling, Michelle
Inhibrx, Inc
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Michelle Darling
Favorite
Das, Bidisha
Brigham and Women's Hospital
(
P 214
)
EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Bidisha Das
Favorite
Daukshus, Nicole
Memorial Sloan Kettering Cancer Center
(
P 307
)
ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Nicole Daukshus
Favorite
Davarifar, Ardy
University of California, Los Angeles
(
P 183
)
OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Ardy Davarifar
Favorite
(
P 184
)
PAN-SARCOMA ORGANOID SCREENING PIPELINE
Ardy Davarifar
Favorite
Davick, Jonathan
University of Iowa Hospitals & Clinics
(
P 159
)
NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Jonathan Davick
Favorite
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Jonathan Davick
Favorite
Davies, Christopher
University College London Cancer Institute
(
P 252
)
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Christopher Davies
Favorite
Davis, Elizabeth
Vanderbilt University Medical Center
(
P 266
)
EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS
Elizabeth Davis
Favorite
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Elizabeth Davis
Favorite
Davis, Lara
Oregon Health & Science University
(
P 310
)
TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Lara Davis
Favorite
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Lara Davis
Favorite
De Almeida, John
Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(
P 290
)
OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
John De Almeida
Favorite
De Andrade, James
Univeristy of Iowa Hospitals & Clinics
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
James De Andrade
Favorite
De Cock, Lore
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute
(
P 198
)
XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Lore De Cock
Favorite
De Heer, Pieter
Department of Surgical Gastroenterology, Copenhagen University Hospital, Rigshospitalet
(
P 120
)
THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Pieter De Heer
Favorite
de la Fuente, Maria Isabel
HCU VIRGEN ARRIXACA
(
P 318
)
NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Maria Isabel de la Fuente
Favorite
de la Maza, Michelina
Banner University Medical Center - Tucson
(
P 208
)
STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PEDIATRIC OSTEOSARCOMA LUNG METASTASES
Michelina de la Maza
Favorite
De Meo, Simone
Orthopedic Oncologic Reconstructive Surgery, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Simone De Meo
Favorite
de Pinieux, Gonzague
Department of Pathology, Université de Tours
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Gonzague de Pinieux
Favorite
De Sutter, Luna
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute
(
P 198
)
XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Luna De Sutter
Favorite
De Toni, Luca
University of Padova
(
P 06
)
GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Luca De Toni
Favorite
De Vita, Alessandro
Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(
P 195
)
THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Alessandro De Vita
Favorite
(
P 250
)
SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Alessandro De Vita
Favorite
Dela Cruz, Filemon
Memorial Sloan Kettering Cancer Center
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Filemon Dela Cruz
Favorite
Delegido-Garcia, Ana
“La Arrixaca” Clinical University Hospital
(
P 055
)
PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Ana Delegido-Garcia
Favorite
(
P 078
)
GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Ana Delegido-Garcia
Favorite
(
P 219
)
PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Ana Delegido-Garcia
Favorite
(
P 281
)
CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Ana Delegido-Garcia
Favorite
Delfour, Christophe
Department for Cell and Tissue Pathobiology of Tumor, Hospital Saint Eloi
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Christophe Delfour
Favorite
Demetri, George
Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School
(
P 099
)
CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
George Demetri
Favorite
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
George Demetri
Favorite
(
P 143
)
A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
George Demetri
Favorite
Demetri, George
IDRx, Inc
(
P 316
)
FIRST-IN-HUMAN PHASE 1/1B STUDY OF IDRX-42, A NOVEL ORAL TYROSINE KINASE KIT INHIBITOR, IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS
George Demetri
Favorite
Demeulemeester, Jonas
VIB-KU Leuven Center for Cancer Biology
(
P 252
)
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Jonas Demeulemeester
Favorite
Demeure, Michael
Hoag Memorial Hospital Presbyterian
(
P 313
)
A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Michael Demeure
Favorite
Demicco, Elizabeth
Mount Sinai Hospital, University of Toronto
(
P 05
)
GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Elizabeth Demicco
Favorite
(
P 124
)
EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
Demicco, Elizabeth
Mount Sinai Hospital, University of Toronto Canada
(
P 180
)
INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Elizabeth Demicco
Favorite
Demicco, Elizabeth
Mount Sinai Hospital, University of Toronto
(
P 190
)
SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
Deming, Dustin
University of Wisconsin
(
P 313
)
A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Dustin Deming
Favorite
DeMonte, Franco
MD Anderson Cancer Center
(
P 013
)
A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Franco DeMonte
Favorite
Deng, Qiumei
Jiangsu Henrui Pharmaceuticals
(
P 136
)
PRELIMINARY EFFICACY AND SAFETY OF FAMITINIB PLUS SHR-1701 IN ADVANCED SARCOMA: A SINGLE-CENTER, PHASE 2 TRIAL
Qiumei Deng
Favorite
DeSalvo, Joanna
University of Miami
(
P 098
)
COMBINATION THERAPY WITH IMATINIB AND PAC-1 INDUCES TREATMENT SYNERGISM IN GASTROINTESTINAL STROMAL TUMORS
Joanna DeSalvo
Favorite
Desar, Ingrid
Radboud University Medical Centre
(
P 103
)
GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Ingrid Desar
Favorite
Desi, Gian Luca
Radiology Service, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Gian Luca Desi
Favorite
Devarajan, Karthik
Fox Chase Cancer Center
(
P 221
)
SURGICAL OUTCOMES OF NEOADJUVANT THERAPY FOR GASTROINTESTINAL STROMAL TUMORS: A SINGLE INSTITUTION ANALYSIS
Karthik Devarajan
Favorite
Dhir, Aditi
University of Miami/Sylvester Comprehensive Cancer Center
(
P 07
)
HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Aditi Dhir
Favorite
(
P 070
)
COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Aditi Dhir
Favorite
(
P 234
)
DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Aditi Dhir
Favorite
Di Lernia, Davide
HG Villalba and Instituto de Investigaciones Sanitarias Fundación Jimenez Diaz
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Davide Di Lernia
Favorite
Di Segni, Susanna
Italian Medicines Agency, Rome, Italy
(
P 162
)
PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Susanna Di Segni
Favorite
Di Somma, Sarah
Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(
P 179
)
IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Sarah Di Somma
Favorite
di Tommaso, Luca
Humanitas University
(
P 056
)
PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Luca di Tommaso
Favorite
Diab, MARIA
Emory University
(
P 041
)
UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
MARIA Diab
Favorite
Diallo, Jean-Simon
Ottawa Hospital Research Institute
(
P 197
)
TUMOR IMMNUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Jean-Simon Diallo
Favorite
Diao, Yarui
Duke University School of Medicine
(
P 254
)
THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA
Yarui Diao
Favorite
Diaz-Beveridge, Roberto
HU La Fe
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Roberto Diaz-Beveridge
Favorite
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Roberto Diaz-Beveridge
Favorite
Dickson, Brendan
Mount Sinai Hospital
(
P 180
)
INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Brendan Dickson
Favorite
Dickson, Mark
Memorial Sloan Kettering Cancer Center
(
P 134
)
PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Mark Dickson
Favorite
(
P 156
)
MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Mark Dickson
Favorite
(
P 167
)
STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Mark Dickson
Favorite
(
P 307
)
ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Mark Dickson
Favorite
Diederich, Aaron
University of Kansas School of Medicine
(
P 276
)
ASSOCIATION OF THE COVID-19 PANDEMIC WITH SOFT TISSUE SARCOMA CHARACTERISTICS
Aaron Diederich
Favorite
(
P 303
)
SMALLER SARCOMAS AT HIGHER RISK FOR POSITIVE SURGICAL MARGINS: A PARADOX OF PROGNOSTIC FACTORS
Aaron Diederich
Favorite
Diederich, Andrew
Kansas University Medical Center
(
P 276
)
ASSOCIATION OF THE COVID-19 PANDEMIC WITH SOFT TISSUE SARCOMA CHARACTERISTICS
Andrew Diederich
Favorite
(
P 303
)
SMALLER SARCOMAS AT HIGHER RISK FOR POSITIVE SURGICAL MARGINS: A PARADOX OF PROGNOSTIC FACTORS
Andrew Diederich
Favorite
Diede, Scott
Merck & Co., Inc..
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Scott Diede
Favorite
Difilippo, Valeria
Lund University
(
P 014
)
A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Valeria Difilippo
Favorite
(
P 024
)
GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Valeria Difilippo
Favorite
Dileo, Palma
University College London Hospitals NHS Foundation Trust
(
P 271
)
ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Palma Dileo
Favorite
Dingley, Brittany
The University of Ottawa
(
P 112
)
PREVALENCE AND PROGNOSTIC VALUE OF TARGETABLE RECEPTORS IN EXTRA-UTERINE LEIOMYOSARCOMA
Brittany Dingley
Favorite
Ding, Li
Aadi Bioscience
(
P 156
)
MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Li Ding
Favorite
Ding, Xiaomin
Shanghai Sixth People's Hospital
(
P 136
)
PRELIMINARY EFFICACY AND SAFETY OF FAMITINIB PLUS SHR-1701 IN ADVANCED SARCOMA: A SINGLE-CENTER, PHASE 2 TRIAL
Xiaomin Ding
Favorite
Dirksen, Uta
University Hospital Essen, Pediatrics III, Essen, Germany
(
P 040
)
TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY
Uta Dirksen
Favorite
(
P 042
)
VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Uta Dirksen
Favorite
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Uta Dirksen
Favorite
Dobosz, Michael
Regeneron Pharmaceuticals
(
P 131
)
MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Michael Dobosz
Favorite
Dobrota, Erika
Indiana University
(
P 192
)
TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Erika Dobrota
Favorite
Dolado, Carmen
HU Canarias
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Carmen Dolado
Favorite
Dong, Yang
Department of Orthopedics,Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(
P 164
)
PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Yang Dong
Favorite
Dorand, Dixon
Vanderbilt University Medical Center
(
P 266
)
EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS
Dixon Dorand
Favorite
D'Orazio, Federico
Department of Radiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(
P 02
)
CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Federico D'Orazio
Favorite
(
P 117
)
SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Federico D'Orazio
Favorite
(
P 224
)
THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Federico D'Orazio
Favorite
(
P 247
)
PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Federico D'Orazio
Favorite
Dorleijn, Desiree
Leiden University Medical Center
(
P 076
)
FOLLOW-UP AFTER CURATIVE SURGICAL TREATMENT OF SOFT-TISSUE SARCOMAS: PATIENTS RECEIVING MORE OR LESS VISITIS THAN PROTOCOL AND ASSOCIATIONS WITH RECURRENCE
Desiree Dorleijn
Favorite
(
P 079
)
HEALTH-RELATED QUALITY OF LIFE OF BONE AND SOFT-TISSUE TUMOR PATIENTS AT TIME OF DIAGNOSIS
Desiree Dorleijn
Favorite
Dorsey*, Jen
Lunenfeld Tanenbaum Research Institute/Mount Sinai Hospital
(
P 05
)
GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Jen Dorsey*
Favorite
(
P 180
)
INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jen Dorsey*
Favorite
Dossa, Fahima
Division of General Surgery, University of Toronto
(
P 05
)
GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Fahima Dossa
Favorite
Dowlati, Afshin
University Hospitals Ahuja Medical Center
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Afshin Dowlati
Favorite
Doyon, Josee
CIUSSS de l'Est-de-l'Île-de-Montréal
(
P 049
)
IMPLEMENTATION OF A ROUTINE DIAGNOSTIC NEXT GENERATION SEQUENCING PANEL OF FUSION-POSITIVE SARCOMAS: A SINGLE CENTER EXPERIENCE
Josee Doyon
Favorite
(
P 308
)
REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Josee Doyon
Favorite
Drabbe, Cas
Netherlands Cancer Institute
(
P 272
)
PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Cas Drabbe
Favorite
Drake, James
Hospital for Sick Children
(
P 124
)
EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
James Drake
Favorite
Drapeau, Isabelle
CIUSSS de l'Est-de-l'Île-de-Montréal
(
P 308
)
REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Isabelle Drapeau
Favorite
Drilon, Alexander
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
Dry, Sarah
UCLA Health
(
P 173
)
DYSREGULATION OF MITOCHONDRIAL DYNAMICS IN WELL-DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA PROVIDES A UNIQUE SUSCEPTABILITY TO NOVEL THERAPY
Sarah Dry
Favorite
(
P 184
)
PAN-SARCOMA ORGANOID SCREENING PIPELINE
Sarah Dry
Favorite
Duan, Zhenfeng
University of Miami
(
P 243
)
MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Zhenfeng Duan
Favorite
DuBois, Steven
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(
P 010
)
SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE
Steven DuBois
Favorite
(
P 023
)
FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Steven DuBois
Favorite
(
P 239
)
FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Steven DuBois
Favorite
Dubray-Longeras, Pascale
Department of Medical Oncology, Centre Jean Perrin
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Pascale Dubray-Longeras
Favorite
Duenas, Daniela
Sarcoma Oncology Research Center
(
P 321
)
PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Daniela Duenas
Favorite
Duffaud, Florence
Department of Medical Oncology, Assistance Publique des Hôpitaux de Marseille, Hôpital La Timone
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Florence Duffaud
Favorite
Dufresne, Armelle
Medical Cancer Department, Centre Léon Bérard
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Armelle Dufresne
Favorite
(
P 238
)
EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Armelle Dufresne
Favorite
Du, Heng
Brigham and Women’s Hospital
(
P 167
)
STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Heng Du
Favorite
Dumitra, Sinziana
McGill University
(
P 220
)
PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Sinziana Dumitra
Favorite
Dutour, Aurélie
CRCL, University Claude Bernard Lyon 1, Lyon, France
(
P 245
)
MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Aurélie Dutour
Favorite
Dutta, Punashi
Natera, Inc
(
P 047
)
FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Punashi Dutta
Favorite
Du, Xinhui
Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(
P 164
)
PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Xinhui Du
Favorite
Dykema, Karl
Atrium Health - Levine Children's Hospital
(
P 246
)
PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Karl Dykema
Favorite
Back to Top
